Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to Buy at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a hold rating to a buy rating in a report released on Wednesday morning, Marketbeat reports. The brokerage currently has $20.00 price objective on the biotechnology company’s stock, up from their previous price objective of $14.00.

Other research analysts have also recently issued research reports about the stock. JMP Securities boosted their price target on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 12th. Evercore ISI lowered their target price on shares of Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research note on Monday, September 15th. HC Wainwright initiated coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They issued a “buy” rating and a $20.00 target price on the stock. Westpark Capital lifted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Wall Street Zen upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 22nd. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $20.83.

Enanta Pharmaceuticals Price Performance

ENTA opened at $10.61 on Wednesday. The business has a fifty day moving average price of $8.25 and a 200 day moving average price of $6.93. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $15.34. The stock has a market capitalization of $226.84 million, a price-to-earnings ratio of -2.46 and a beta of 0.88.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%.The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million. On average, research analysts anticipate that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Several large investors have recently modified their holdings of the company. US Bancorp DE purchased a new position in shares of Enanta Pharmaceuticals during the first quarter worth approximately $36,000. GAMMA Investing LLC purchased a new position in Enanta Pharmaceuticals during the 1st quarter worth $40,000. Farther Finance Advisors LLC grew its position in Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 5,779 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Enanta Pharmaceuticals in the fourth quarter valued at $66,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of Enanta Pharmaceuticals in the first quarter valued at about $72,000. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.